Author: Ravi Shankar

SIKA FURTHER STRENGTHENS LOCAL PRESENCE BY ACQUIRING WATERPROOFING COMPANY IN THE UAE

Sika has acquired Duproof, a Dubai-based manufacturer of waterproofing membranes. The acquisition strengthens Sika’s position in the rapidly growing UAE construction market and supports Sika’s locally sourced product offering for projects in the region.

Duproof manufactures a broad range of bituminous membrane solutions that are widely used in major construction projects across the UAE. The brand enjoys strong recognition among contractors and applicators. The company operates a highly efficient, strategically located production site which will drive manufacturing and distribution synergies for Sika.

KEY BENEFITS OF THE ACQUISITION

• Expanding Product Offering for Major Projects: Sika will build on its well-established position in the UAE by integrating Duproof’s bituminous membranes into specifications of major projects, supported by its strong sales organization and established customer network. Waterproofing systems are a critical element across all infrastructure, non-residential, and residential projects. The ability to supply locally produced bituminous membranes will enable Sika to grow share across all construction segments.
• Complementary Channels: Duproof’s waterproofing membranes will be available through Sika UAE’s distributor network while Sika will gain access to Duproof’s strong network of contractors and applicators, creating meaningful cross-selling opportunities.
• Strengthening Regional Supply Chain: Through the acquisition of Duproof, Sika further strengthens its regional waterproofing platform in the Middle East. Complementing its existing manufacturing footprint in Saudi Arabia and Egypt, the new UAE site enhances the ability to serve customers across the region through local manufacturing and regional supply capabilities.

Christoph Ganz, Sika Regional Manager EMEA: “The acquisition of Duproof will further enhance our competitive position by strengthening our supply chain in the region. The added new customer relationships and product solutions perfectly complement our existing offering. Leveraging Duproof’s capabilities through our strong sales organization will unlock significant cross-selling opportunities and increase our share of wallet in major projects. We warmly welcome the Duproof team to our Sika family and look forward to developing our business together.”

SIKA CORPORATE PROFILE
Sika is a specialty chemicals company with a globally leading position in the development and production of systems and products for bonding, sealing, damping, reinforcing, and protection in the building sector and industry. Sika has subsidiaries in 103 countries around the world, produces in over 400 factories, and develops innovative technologies for customers worldwide. In doing so, it plays a crucial role in enabling the transformation of the construction and transportation industries toward greater environmental compatibility. In 2025, Sika’s 33,700 employees generated annual sales of CHF 11.20 billion.

CONTACT
Dominik Slappnig
Corporate Communications and
Investor Relations
+41 58 436 68 21
slappnig.dominik@ch.sika.com

The media release can be downloaded from the following link:
Media Release 

Andrew Murray joins as Senior Vice President to deepen Nasdaq’s Financial Technology client partnerships across Asia-Pacific as the region enters a defining era of market evolution

Bob McCooey, Vice Chairman and Head of International Listings, relocates to Singapore to broaden access to global capital for the region’s companies and investors

SINGAPORE, Oct. 25, 2026 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced the appointment of Andrew Murray as Senior Vice President, Financial Technology, Asia-Pacific, strengthening its senior presence in one of the world’s most dynamic regions. Based in Singapore, Murray will deepen Nasdaq’s Financial Technology client partnerships and accelerate business growth across Asia-Pacific, supporting financial institutions as they deliver on their technology and transformation priorities. His appointment follows the relocation to Singapore of Bob McCooey, Vice Chairman and Head of International Listings, a move that enhances Nasdaq’s engagement with the region’s companies and their access to global capital.

These developments position Nasdaq to help advance the region’s technology and capital markets ambitions.

“Asia-Pacific is entering one of the most significant cycles of innovation and market evolution in decades, driven by AI, data and the move toward always-on, globally connected markets,” said Valerie Bannert-Thurner, Executive Vice President and Chief Revenue Officer, Financial Technology at Nasdaq. “Andrew’s strong track record of helping financial institutions solve complex technology challenges will be invaluable as our clients navigate this rapidly changing landscape. Alongside Bob and our teams across the region, we are committed to being a trusted, long-term partner to Asia-Pacific’s market ecosystems.”

Murray brings more than three decades of experience leading teams and building long-term client partnerships at financial technology companies serving treasury, trading, corporate banking and capital markets clients. Most recently, he served as a leader in International Banking and Payments at FIS, where he supported clients across the full banking and payments value chain. His career includes senior international leadership positions at FIS in Banking & Markets and Post-Trade Solutions, as well as previous experience at Calypso Technology (now part of Nasdaq), SunGard, Wall Street Systems and Deutsche Bank.

“Asia-Pacific’s ambition is reshaping the global economy, and the region’s companies and investors increasingly seek access to deep, global pools of capital to fuel that growth,” said Bob McCooey, Vice Chairman and Head of International Listings at Nasdaq. “Strengthening our presence on the ground will allow us to work more closely with the region’s companies, investors and market participants, and deepen our role as a long-term partner across Asia-Pacific. Together, we can bring the full breadth of Nasdaq to support the innovation and economic growth that define this region.”

McCooey’s relocation underscores Nasdaq’s commitment to broadening access to capital and supporting the development of companies and economies across Asia-Pacific. With more than two decades at Nasdaq, McCooey has partnered with many of the region’s most innovative companies on their journeys to the global capital markets. Being based in Singapore will facilitate closer collaboration with clients, partners and local market ecosystems.

Basing two additional senior leaders in Singapore also reflects Nasdaq’s enduring commitment to Asia-Pacific. As the region’s markets become more connected, continuous and technology-driven, Nasdaq will continue to partner with clients, exchanges and market ecosystems to strengthen the trusted infrastructure that supports capital formation and long-term economic growth.

Notes to editors

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying the technology, data, and advanced analytics that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Media Contacts: 

Sophie Sophaon; +852 6305 7060; Sophie.Sophaon@nasdaq.com

Andrew Hughes; +44 (0)7443 100896; Andrew.Hughes@nasdaq.com

-NDAQG-

OpenWorld (“OPNW”) stockholders will be able to hold and trade a blockchain version of their existing shares on Figure OPEN alongside the Company’s Nasdaq listing with no shareholder dilution

LAKE MARY, Fla., Oct. 25, 2026 (GLOBE NEWSWIRE) — OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a blockchain innovation company advancing real-world asset tokenization, today confirmed that its planned dual listing on Figure’s On-chain Public Equity Network (“Figure OPEN”) remains on track to go live in the fourth quarter of 2026.

OpenWorld expects to be among the first Nasdaq-listed companies to bring its public equity on-chain, giving institutional and retail investors a new way to hold and trade shares of a U.S. exchange-listed company without leaving the regulatory boundaries of the existing securities framework.

The update follows stockholder approval on October 16, 2026 of the Company’s Amended and Restated Articles of Incorporation (“Restated Articles”), which authorizes a new class of Blockchain Common Stock. As disclosed in the Company’s Current Report on Form 8-K filed on October 16, 2026. This is the corporate mechanism required to bring OpenWorld’s equity onto Figure OPEN.

No New Shares – One Company, Two Ways to Trade

The Figure OPEN listing does not involve the issuance of any new shares and will not raise capital. OpenWorld’s Blockchain Common Stock will serve as a blockchain-native version of the Company’s existing Nasdaq-listed shares, giving stockholders the choice of holding and trading OPNW shares on Nasdaq or on Figure OPEN. Blockchain Common Stock is designed to settle in real time, rather than on the conventional T+1 cycle, and to trade around the clock. The Company’s total number of outstanding shares will not increase.

“Bringing OPNW on-chain has been part of our vision since day one, and we remain on track to execute this vision with Figure OPEN later this quarter,” said Matthew Shaw, Chief Executive Officer and Chairman of OpenWorld. “Bringing our shares on-chain through Figure OPEN provides our existing stockholders with greater choice, without any dilution, as markets increasingly move 24/7 through blockchain rails. When we go live on Figure OPEN, our shareholders can trade on Nasdaq as they always have or hold the same ownership as a blockchain-native share with faster settlement and extended trading access. We believe this is where public markets are heading, and we intend to be at the front of it.”

Delivering on the Dual-Listing Plan

As announced on October 1, 2026, OpenWorld is pursuing a dual listing on Figure OPEN, building on its previously announced agreement with Figure Technology Solutions, Inc. (NASDAQ: FIGR) to offer a digitally native share class. With stockholder approval secured, OpenWorld expects the Figure OPEN listing to be live later this quarter.

The Figure OPEN listing is designed to complement, not replace, the Company’s Nasdaq listing. OpenWorld remains subject to the same SEC reporting requirements, corporate governance standards and investor protections.

Compliant Transfer Agent to Simplify the Dual Structure

To make moving between the two formats simple for stockholders, OpenWorld has appointed Vinyl Equity, Inc., an SEC-registered transfer agent equipped to maintain records for both traditional and blockchain-based shares. The transfer agent will support stockholders who wish to hold their shares in either form. OpenWorld will provide information on how stockholders can access the blockchain-based shares.

Charter Amendments Approved

On September 30, 2026, OpenWorld’s Board of Directors approved the Restated Articles and submitted them to stockholders. On October 16, 2026, stockholders holding approximately 57.57% of the Company’s issued and outstanding common stock, a majority of its outstanding voting power, approved the Restated Articles by written consent under Section 78.320 of the Nevada Revised Statutes. The amendments provide for:

• The authorization of 500,000,000 shares of Blockchain Common Stock, par value $0.001 per share, as a “blank check” class issuable in one or more series.
• An express election permitting the Company to make distributions that would otherwise be prohibited by NRS 78.288(2)(b).

Upon effectiveness, OpenWorld’s authorized capital stock will consist of 675,000,000 shares of Common Stock, 500,000,000 shares of Blockchain Common Stock and 75,000,000 shares of Preferred Stock, each with a par value of $0.001 per share. Authorized shares represent the maximum the Company may issue and do not change the number of shares outstanding. The Restated Articles will become effective upon filing with the Nevada Secretary of State following the expiration of the applicable notice period under Rule 14c-2 under the Securities Exchange Act of 1934, as amended, following the mailing of OpenWorld’s definitive Information Statement on Schedule 14C to its stockholders, which is expected to begin on October 26, 2026.

About OpenWorld

OpenWorld, Inc. (NASDAQ: OPNW) is a digital assets and blockchain technology company. Through its OpenWorld Enterprise platform, the Company provides financial structuring and blockchain infrastructure for the issuance and distribution of tokenized real-world assets to institutional and retail investors. To learn more, visit openworld.dev.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the timing of filing and effectiveness of the Company’s Restated Articles, the timing of the Company’s definitive Information Statement on Schedule 14C being mailed to the Company’s stockholder, the timing and expected benefits of the Company’s listing on Figure OPEN, the issuance and characteristics of Blockchain Common Stock, and the services of the Company’s transfer agent. Words such as “believe,” “expects,” “intends,” “planned,” “will,” and similar expressions identify forward-looking statements. These statements are subject to risks and uncertainties, including regulatory approvals, market conditions and technology readiness, that could cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this release. OpenWorld undertakes no obligation to update them except as required by law. Additional risks are described in the Company’s filings with the SEC.

Contacts

Investors: OpenWorldIR@allianceadvisors.com

Media: Aayushi@allianceadvisors.comTransfer

NMS Equity Transfer Agent: Vinyl Equity, Inc., 1-888-80-VINYL (84695)

Blockchain Equity Transfer Agent: Figure Equity Solutions, Inc., support@figuremarkets.com

Source: Form 8-K filed with the SEC.

Prior announcements: October 1 Nasdaq listing; Figure agreement.

— ORPATHYS^® plus TAGRISSO^® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO^® —

— ORPATHYS^® plus TAGRISSO^® extended median OS by nearly 5 months —

— SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting —

— Establishes ORPATHYS^® plus TAGRISSO^® as an important targeted strategy to address MET-driven resistance following progression on prior EGFR TKI treatment —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 25, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces positive results from the SAFFRON global Phase III trial. ORPATHYS^® (savolitinib) plus TAGRISSO^® (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival (“PFS”) and overall survival (“OS”) versus doublet platinum-based chemotherapy in patients with epidermal growth factor receptor-mutated (“EGFRm”) non-small cell lung cancer (“NSCLC”). Patients in the trial had tumors with high levels of MET overexpression or amplification and had progressed on prior treatment with TAGRISSO^®.

These results have been presented during the Presidential Symposium at the European Society for Medical Oncology (“ESMO”) Congress in Madrid, Spain (abstract #LBA6).¹ They were also simultaneously published in The New England Journal of Medicine 2026. Featuring prominently on oncology’s premier stage and in a flagship journal underscores the pivotal nature of the SAFFRON trial in redefining the treatment paradigms for MET-driven EGFRm NSCLC. The data validate ORPATHYS^® combined with TAGRISSO^® as a landmark, all-oral strategy to address the major unmet need of MET-driven resistance after third-generation epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) therapy.

Results showed ORPATHYS^® plus TAGRISSO^® reduced the risk of disease progression or death by 45% compared to chemotherapy (based on a PFS hazard ratio [“HR”] of 0.55; 95% confidence interval [“CI”] 0.42-0.72; p<0.001). Median PFS as assessed by blinded independent central review (“BICR”) was 7.6 months for ORPATHYS^® plus TAGRISSO^® versus 5.4 months for the comparator arm. An estimated 36% of patients treated with the combination were progression-free at one year compared to 10% in the comparator arm. Importantly, the PFS benefit observed was consistent across all prespecified subgroups, including patients whose tumor had MET-overexpression or MET-amplification.

Results for the key secondary endpoint of OS showed ORPATHYS^® plus TAGRISSO^® reduced the risk of death by 32% versus chemotherapy (OS HR 0.68; 95% CI 0.50-0.91; p=0.010). ORPATHYS^® plus TAGRISSO^® extended median OS by 4.9 months versus the comparator arm (17.8 versus 12.9 months). An estimated 70% of patients treated with the combination were alive at one year compared to 53% in the comparator arm.

Professor Shun Lu, Director of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine and global leading principal investigator of the trial, said: “These results have the potential to establish a new global standard of care for the third of patients with EGFR-mutated non-small cell lung cancer experiencing MET-driven resistance after osimertinib. There are currently no well-tolerated, oral, biomarker-directed treatment options to address this frequent driver of disease progression. Savolitinib plus osimertinib significantly extended median overall survival by nearly five months in this later-line setting, establishing a new clinical benchmark and reinforcing the critical need for MET testing to guide patient care.”

Mr Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer of HUTCHMED, said: “These data from SAFFRON mark a decisive step forward in targeting MET-driven resistance — a longstanding challenge in EGFR-mutated lung cancer. Precision inhibition with ORPATHYS^® alongside TAGRISSO^® offers a meaningful, all-oral option for patients with disease progression. We are delighted to see that our partnership with AstraZeneca continues to deliver impactful innovations that have the potential to redefine standard of care and improve outcomes for patients globally.”

Dr Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “These data show combining ORPATHYS^® with backbone therapy TAGRISSO^® directly addresses MET-driven resistance while maintaining EGFR suppression, building on the established efficacy, safety and central nervous system protection of TAGRISSO^®. With the potential to become the first biomarker-directed, all-oral treatment option in this setting, this combination further strengthens our leadership in EGFR-mutated lung cancer and reflects our strategy of matching the right therapy to the underlying drivers of disease at every stage.”

Summary of PFS and OS results: SAFFRON ⁱ

	ORPATHYS® + TAGRISSO® (n=171)	Chemotherapy (n=167)
PFS by BICR: Full Analysis Set (FAS)
Number of patients with event, n (%)	117 (68.4)	113 (67.7)
Median PFS (95% CI) (in months)	7.6 (5.6-9.7)	5.4 (4.2-5.8)
HR (95% CI)	0.55 (0.42-0.72)
p-value	p<0.001
PFS rate at 12 months (%)	36	10
OS: FAS
Number of deaths, n (%)	87 (50.9)	93 (55.7)
Median OS (95% CI) (in months)	17.8 (15.6-23.7)	12.9 (10.6-16.8)
HR (95% CI)	0.68 (0.50-0.91)
p-value	p=0.010
OS rate at 12 months (%)	70	53
PFS by BICR: MET-overexpressed analysis set
Number of patients, n	127	118
Number of patients with event, n (%)	77 (60.6)	80 (67.8)
Median PFS (95% CI) (in months)	8.5 (5.7-11.1)	5.6 (4.4-6.7)
HR (95% CI)	0.51 (0.37-0.71)
p-value	p<0.001
PFS rate at 12 months (%)	40	11
PFS by BICR: MET-amplified analysis set ii
Number of patients, n	129	116
Number of patients with event, n (%)	89 (68.9)	79 (68.1)
Median PFS (95% CI) (in months)	7.64 (5.6-9.7)	4.2 (3.1-5.5)
HR (95% CI)	0.487 (0.35-0.66)
PFS rate at 12 months (%)	33	8
i  OS and PFS data cut-off was 6 July 2026.  ii No formal statistical testing was carried out for the MET-amplified analysis set

The safety profile for ORPATHYS^® plus TAGRISSO^® was manageable and consistent with the known profiles of each medicine, and there were no new safety concerns. Grade 3 or higher treatment-emergent adverse events from all causes occurred in 64% of patients treated with ORPATHYS^® plus TAGRISSO^® and 63% of patients in the comparator arm. Median total duration of treatment exposure was more than twice as long for ORPATHYS^® plus TAGRISSO^® (8.5 months) compared with the comparator arm (3.5 months).

Based on the SAFFRON Phase III trial results, a New Drug Application (“NDA”) for ORPATHYS^® plus TAGRISSO^® were submitted to the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic NSCLC whose tumors have high levels of MET overexpression or amplification and who had disease progression on or after an EGFR-TKI therapy. An NDA submission in Europe and Japan is also progressing as planned. ORPATHYS^® plus TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFRm-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial.

Results from the SANOVO Phase III trial evaluating ORPATHYS^® plus TAGRISSO^® in treatment-naïve patients in China with EGFRm locally advanced or metastatic NSCLC and MET overexpression will be presented during a Proffered Paper session at the ESMO Congress (abstract #LBA69). ²

ORPATHYS^® is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

About NSCLC and MET aberrations

Lung cancer is the leading cause of cancer death globally, accounting for almost one in four (23%) cancer deaths.^3,4 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% of patients diagnosed with NSCLC.⁵ Approximately 75% of NSCLC patients are diagnosed with advanced disease.⁶ Additionally, about 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia, have EGFRm NSCLC.^​7

MET is a tyrosine kinase receptor that has an essential role in normal cell development.⁸ MET overexpression or amplification can lead to tumor growth and the metastatic progression of cancer cells.^8,9 Approximately one in three patients’ tumors will develop high levels of MET overexpression or amplification (IHC3+>90% and FISH10+) after progression on a third-generation EGFR-TKI.¹⁰

About SAFFRON

SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of ORPATHYS^® (300 mg twice daily) added to TAGRISSO^® (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO^®. The trial enrolled patients in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.

Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. ​In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.

About ORPATHYS^®

ORPATHYS^® (savolitinib) is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.

ORPATHYS^® is approved in China for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. ORPATHYS^® also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. ORPATHYS^® in combination with TAGRISSO^® is approved in China for patients with locally advanced or metastatic EGFR mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO^®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in PFS and OS in August 2026.

About TAGRISSO^®

TAGRISSO^® (osimertinib) is a third-generation, irreversible EGFR TKI with proven clinical activity in NSCLC, including the treatment of central nervous system metastases.

TAGRISSO^® is approved as monotherapy in more than 120 countries including the US, EU, China and Japan. Approved indications include for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, adjuvant treatment of early-stage EGFRm NSCLC and locally advanced, unresectable NSCLC following platinum-based chemoradiation therapy. TAGRISSO^® is also approved in combination with chemotherapy in more than 80 countries, including the US, EU, China and Japan, for first-line treatment of patients with locally advanced or metastatic EGFRm NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of ORPATHYS^®, the further clinical development for ORPATHYS^®, its expectations as to whether any studies on ORPATHYS^® would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of ORPATHYS^®, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of ORPATHYS^® for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize ORPATHYS^®. In addition, as certain studies rely on the use of other drug products such as TAGRISSO^® as combination therapeutics with ORPATHYS^®, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

 

REFERENCES
1	Lu S, et al. Osimertinib [osi] + savolitinib [savo] vs platinum–pemetrexed [plat–pem] in EGFRm MET-overexpressed [OE] and/or -amplified [AMP] advanced NSCLC post-osi: SAFFRON Phase [Ph] 3 primary results. Presented in a Proffered Paper session during Presidential Symposium II the European Society for Medical Oncology Congress 2026, 25 October at 16:45 CET.
2	Wu YL, et al. Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study. Presented at the European Society for Medical Oncology Congress 2026, 26 October at 08:30 CET.
3	World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf. Accessed October 2026.
4	World Health Organization. International Agency for Research on Cancer. All Cancers Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf. Accessed October 2026.
5	American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.
6	Chen HJ, et al. Long-term survival of advanced lung adenocarcinoma by maintenance chemotherapy followed by EGFR-TKI. Medicine. 2021;100(6):e24688.
7	Gao X, et al. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2016;16(4):383-390.
8	Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(4074)
9	Wang Q, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;63.
10	De Marinis F, et al. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. Ann Oncol. 2025;36(8):920-933.

OpenWorld (“OPNW”) stockholders will be able to hold and trade a blockchain version of their existing shares on Figure OPEN alongside the Company’s Nasdaq listing with no shareholder dilution

LAKE MARY, Fla., Oct. 25, 2026 (GLOBE NEWSWIRE) — OpenWorld, Inc. (NASDAQ: OPNW) (“OpenWorld” or the “Company”), a blockchain innovation company advancing real-world asset tokenization, today confirmed that its planned dual listing on Figure’s On-chain Public Equity Network (“Figure OPEN”) remains on track to go live in the fourth quarter of 2026.

OpenWorld expects to be among the first Nasdaq-listed companies to bring its public equity on-chain, giving institutional and retail investors a new way to hold and trade shares of a U.S. exchange-listed company without leaving the regulatory boundaries of the existing securities framework.

The update follows stockholder approval on October 16, 2026 of the Company’s Amended and Restated Articles of Incorporation (“Restated Articles”), which authorizes a new class of Blockchain Common Stock. As disclosed in the Company’s Current Report on Form 8-K filed on October 16, 2026. This is the corporate mechanism required to bring OpenWorld’s equity onto Figure OPEN

No New Shares – One Company, Two Ways to Trade

The Figure OPEN listing does not involve the issuance of any new shares and will not raise capital. OpenWorld’s Blockchain Common Stock will serve as a blockchain-native version of the Company’s existing Nasdaq-listed shares, giving stockholders the choice of holding and trading OPNW shares on Nasdaq or on Figure OPEN. Blockchain Common Stock is designed to settle in real time, rather than on the conventional T+1 cycle, and to trade around the clock. The Company’s total number of outstanding shares will not increase.

“Bringing OPNW on-chain has been part of our vision since day one, and we remain on track to execute this vision with Figure OPEN later this quarter,” said Matthew Shaw, Chief Executive Officer and Chairman of OpenWorld. “Bringing our shares on-chain through Figure OPEN provides our existing stockholders with greater choice, without any dilution, as markets increasingly move 24/7 through blockchain rails. When we go live on Figure OPEN, our shareholders can trade on Nasdaq as they always have or hold the same ownership as a blockchain-native share with faster settlement and extended trading access. We believe this is where public markets are heading, and we intend to be at the front of it.”

Delivering on the Dual-Listing Plan

As announced on October 1, 2026, OpenWorld is pursuing a dual listing on Figure OPEN, building on its previously announced agreement with Figure Technology Solutions, Inc. (NASDAQ: FIGR) to offer a digitally native share class. With stockholder approval secured, OpenWorld expects the Figure OPEN listing to be live later this quarter.

The Figure OPEN listing is designed to complement, not replace, the Company’s Nasdaq listing. OpenWorld remains subject to the same SEC reporting requirements, corporate governance standards and investor protections.

Compliant Transfer Agent to Simplify the Dual Structure

To make moving between the two formats simple for stockholders, OpenWorld has appointed Vinyl Equity, Inc., an SEC-registered transfer agent equipped to maintain records for both traditional and blockchain-based shares. The transfer agent will support stockholders who wish to hold their shares in either form. OpenWorld will provide information on how stockholders can access the blockchain-based shares.

Charter Amendments Approved

On September 30, 2026, OpenWorld’s Board of Directors approved the Restated Articles and submitted them to stockholders. On October 16, 2026, stockholders holding approximately 57.57% of the Company’s issued and outstanding common stock, a majority of its outstanding voting power, approved the Restated Articles by written consent under Section 78.320 of the Nevada Revised Statutes. The amendments provide for:

• The authorization of 500,000,000 shares of Blockchain Common Stock, par value $0.001 per share, as a “blank check” class issuable in one or more series.
• An express election permitting the Company to make distributions that would otherwise be prohibited by NRS 78.288(2)(b).

Upon effectiveness, OpenWorld’s authorized capital stock will consist of 675,000,000 shares of Common Stock, 500,000,000 shares of Blockchain Common Stock and 75,000,000 shares of Preferred Stock, each with a par value of $0.001 per share. Authorized shares represent the maximum the Company may issue and do not change the number of shares outstanding. The Restated Articles will become effective upon filing with the Nevada Secretary of State following the expiration of the applicable notice period under Rule 14c-2 under the Securities Exchange Act of 1934, as amended, following the mailing of OpenWorld’s definitive Information Statement on Schedule 14C to its stockholders, which is expected to begin on October 26, 2026.

About OpenWorld

OpenWorld, Inc. (NASDAQ: OPNW) is a digital assets and blockchain technology company. Through its OpenWorld Enterprise platform, the Company provides financial structuring and blockchain infrastructure for the issuance and distribution of tokenized real-world assets to institutional and retail investors. To learn more, visit openworld.dev.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the timing of filing and effectiveness of the Company’s Restated Articles, the timing of the Company’s definitive Information Statement on Schedule 14C being mailed to the Company’s stockholder, the timing and expected benefits of the Company’s listing on Figure OPEN, the issuance and characteristics of Blockchain Common Stock, and the services of the Company’s transfer agent. Words such as “believe,” “expects,” “intends,” “planned,” “will,” and similar expressions identify forward-looking statements. These statements are subject to risks and uncertainties, including regulatory approvals, market conditions and technology readiness, that could cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this release. OpenWorld undertakes no obligation to update them except as required by law. Additional risks are described in the Company’s filings with the SEC.

Contacts

Investors: OpenWorldIR@allianceadvisors.com   

Media: Aayushi@allianceadvisors.comTransfer 

NMS Equity Transfer Agent: Vinyl Equity, Inc., 1-888-80-VINYL (84695)

Blockchain Equity Transfer Agent: Figure Equity Solutions, Inc., support@figuremarkets.com 

Source: Form 8-K filed with the SEC.

Prior announcements: October 1 Nasdaq listing; Figure agreement.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1881bca4-3fc3-4014-824c-36b701b0b84e

Frøya, 25 October 2026: Reference is made to the Company’s announcement of 1 October 2026 regarding the waiver agreement with its lenders. As 25 October 2026 falls on a non-banking day, the lenders have agreed to extend the waiver period until and including Monday, 26 October 2026. The Company remains in dialogue with its lenders and relevant stakeholders regarding its financing position and will provide a further update when appropriate.

For further information, please contact:
Vidar Aspehaug, CEO: +47 913 05 017 (mobile)
Þórunn Ragnarsdóttir, CFO: +354 822 7649 (mobile)

About Kaldvík AS

Kaldvík  AS is  the leading  salmon farmer  in Iceland.  Kaldvik AS  has a well-developed  and fully integrated  value-chain, enabling the  group to provide its customers  with  a  sustainable  premium  product.  Kaldvik AS is dual listed on Euronext   Growth   Oslo   and   First   North   Iceland   Growth   Market.  See https://www.kaldvik.is for more information about the Company.

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

Webcast Details

Oruka Therapeutics’ live webcast of the EVERLAST-B results will begin on Monday, October 26^th, at 8:00 a.m. ET. The live webcast can be accessed via this link, or through the Investors section on the company’s website at https://ir.orukatx.com/news-events/events-presentations. A replay of the webcast will be available following the call.

About Oruka Therapeutics

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidradenitis suppurativa the greatest possible freedom from their condition by achieving high rates of disease clearance with dosing as infrequently as once or twice a year. For more information, visit www.orukatx.com and follow Oruka on LinkedIn. 

Investor Contact: 
Alan Lada 
(650)-606-7911 
alan.lada@orukatx.com   

• Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study^1,2
• At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib^1,2
• No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly low grade and manageable^1,2
• Data presented as a late-breaking abstract during a Presidential Symposium at the 2026 ESMO Congress and simultaneously published in The New England Journal of Medicine^1,2

Basel, 25 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).^1,2 Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005).^1,2 Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below).^1,2 No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable.^1,2 These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.^1,2

“The phase III Krascendo 1 results demonstrate the potential for divarasib to become a new standard of care for people with previously treated KRAS G12C-mutated lung cancer,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The superior efficacy against the current standard of care demonstrated in this head-to-head trial reinforces divarasib’s best-in-class profile. We are working closely with health authorities to bring this new treatment option to the people who need it.”

The G12C mutation is one of the most common KRAS mutations, found in approximately one in eight people with NSCLC.^3,4 Accumulating evidence suggests that people with NSCLC who have the KRAS G12C mutation may have poorer outcomes than those who have the unmutated KRAS gene (wild-type disease).^5,6 Despite the approval of current, first-generation KRAS G12C-targeted treatments, there remains a significant unmet need for more effective therapy options.

“New life-extending treatments are greatly needed, as most patients with this type of cancer will eventually relapse after initial therapy, and there are limited effective treatments for recurrent disease,” said study lead author Ferdinandos Skoulidis, MD, PhD, Professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. “The Krascendo 1 results highlight divarasib’s practice-changing potential, as the first KRAS inhibitor to meaningfully improve overall survival for people with previously treated KRAS G12C-mutated lung cancer, compared with current treatment options.”

The Krascendo 1 study is the only global head-to-head study to evaluate a next-generation KRAS G12C inhibitor versus approved first-generation KRAS G12C inhibitors.^1,2 The study met primary and key secondary endpoints, and divarasib demonstrated statistically significant and clinically meaningful improvements in OS and progression-free survival (PFS) over sotorasib or adagrasib.^1,2 In addition to the OS benefit, divarasib reduced the risk of disease progression or death by 42% (PFS HR 0.58, [95% CI: 0.44-0.76], p<0.0001).^1,2 The OS and PFS benefit was consistent across clinically relevant subgroups, and was observed regardless of PD-L1 expression or KEAP1 mutation status.^1,2 The objective response rate (ORR) with divarasib was nearly double that of sotorasib or adagrasib.^1,2

Key efficacy results from the phase III Krascendo 1 study:^1,2

Primary and key secondary endpoints	Divarasib arm (n=167)*	Control arm (adagrasib, sotorasib) (n=171)*	Hazard Ratio / (95% CI)	p-value
Median OS (months)	17.7	12.0	HR 0.56 (0.41-0.78)	p=0.0005
Median PFS (months)	9.8	5.7	HR 0.58 (0.44-0.76)	p<0.0001
12-month PFS rate (%)	44%	24%	–	–
Confirmed ORR (%)*	58%	32%	–	–
Median DOR (months)*	11.9	6.9	–	–

*Assessed in response-evaluable population (n=328; ten patients [divarasib arm, n=6; control arm, n=4] did not have measurable disease at baseline and were excluded from the response-evaluable set). Duration of Response (DOR) evaluated in those who responded to treatment (divarasib arm, n=94; control arm, n=54).

The safety profile of divarasib monotherapy was consistent with the known class effects of KRAS G12C inhibitors.^1,2 The most common TRAEs comprised GI toxicity (most commonly, diarrhoea, nausea, and vomiting) and hepatotoxicity.^1,2 Fewer participants discontinued treatment due to TRAEs with divarasib (4.8% versus 11.7%) and the rate of serious TRAEs was approximately half that of sotorasib or adagrasib (7.8% versus 15.2% respectively), despite patients remaining on treatment for more than twice as long (11.3 months compared with 5.0 months).^1,2

Roche is advancing a comprehensive phase III clinical development programme in NSCLC, investigating divarasib as both a monotherapy and as a chemotherapy-free combination, across different disease settings and lines of therapy. The US Food and Drug Administration granted Breakthrough Therapy Designation to divarasib in 2022, and in 2026, Orphan Drug Designation for KRAS G12C-mutated NSCLC.

About Krascendo 1^1,2
The Krascendo 1 study [NCT06497556] is the only global head-to-head study evaluating a Kirsten rat sarcoma virus (KRAS) G12C inhibitor in direct comparison with first-generation approved KRAS G12C inhibitors. This phase III, randomised, open-label, multicentre study evaluates the efficacy and safety of divarasib monotherapy versus sotorasib or adagrasib in people with previously treated KRAS G12C-mutated advanced or metastatic non-small cell lung cancer. The study includes 338 adults, randomised to receive either divarasib once daily (n=167) or, either sotorasib once daily or adagrasib twice daily (n=171). The primary endpoint is blinded independent central review (BICR)-assessed progression-free survival. Secondary endpoint measures include overall survival, confirmed objective response, duration of response, as well as other efficacy and safety measures.

About divarasib
Divarasib is an investigational, best-in-class, next-generation, oral, KRAS G12C inhibitor, discovered and developed by researchers within Roche and Genentech. It has shown greater potency and selectivity in preclinical studies compared with first-generation KRAS G12C-targeting treatments, sotorasib or adagrasib, with superior efficacy demonstrated in people with previously treated KRAS G12C-mutated NSCLC.^1,2,7 Divarasib is designed to selectively bind to the KRAS G12C protein, locking the protein in an inactive (off) state, thereby turning off its tumour-driving signalling.^7,8,9

Divarasib’s comprehensive clinical development programme is anchored by three phase III studies:

Study	Intervention	Patient population
Krascendo 1 [NCT06497556]	Divarasib monotherapy vs sotorasib or adagrasib	Previously treated KRAS G12C-mutated  advanced or metastatic NSCLC (second-line)
Krascendo 2 [NCT06793215]	Divarasib plus pembrolizumab (chemotherapy-free combination) vs chemotherapy plus pembrolizumab	Previously untreated KRAS G12C-mutated advanced NSCLC (first-line)
Krascendo 3 [NCT07541170]	Adjuvant divarasib monotherapy vs immunotherapy or observation	Resected stage II–IIIB KRAS G12C-mutated NSCLC after standard of care chemoimmunotherapy (early-stage)

Divarasib underpins Roche’s diversified pipeline targeting the RAS signalling pathway, including other mutant-selective inhibitors and a pan-RAS inhibitor, designed to extend the benefits of RAS inhibition strategies to more patients.

About KRAS G12C-mutated non-small cell lung cancer
Despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths worldwide, surpassing the combined mortality rates of breast, prostate, and stomach cancers.^10,11 Each year, it claims the lives of 1.8 million people, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases.^10,12 KRAS is one of the most frequently mutated genes in lung cancer, occurring in approximately 25% of newly diagnosed lung cancers, and is associated with poor prognosis for patients.⁹ The G12C mutation is one of the most common KRAS mutations, found in approximately 12-14% of NSCLC cases.^3,4

The KRAS gene produces the KRAS protein, which acts as a cellular control switch, cycling between an active (on) and inactive (off) state to regulate cell growth and proliferation, making it a critical target for new therapeutic strategies.⁹ G12C mutation locks the KRAS protein in its active (on) state, leading to continuous, unregulated signalling for cell growth, driving tumour proliferation.^8,9

About Roche in lung cancer
Roche is committed to advancing the field of lung cancer treatments, leveraging more than 20 years of deep scientific expertise to improve patient outcomes and their overall experience. Roche’s strong commitment to investment in research and development has built a robust portfolio of approved medicines and companion diagnostics, which empowers physicians to better understand a patient’s disease and optimise care.

Roche’s broad portfolio includes approved medicines such as Alecensa® (alectinib), Tecentriq® (atezolizumab), and Rozlytrek® (entrectinib). Its extensive pipeline includes investigational treatments across three key focus areas: small cell lung cancer, non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGA), and NSCLC without AGA. Utilising diverse approaches, ranging from cancer-cell-killing ‘cytotoxics’ and immunotherapies to treatments targeting specific characteristics of cancer cells, we aim to translate scientific discoveries into meaningful progress in patient care.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Skoulidis F, et al. Krascendo 1: efficacy and safety of divarasib vs sotorasib or adagrasib in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. Presented at: ESMO Congress; 2026 October 23-27; Madrid, Spain. #LBA5.
[2] Skoulidis F, et al. Divarasib as compared with sotorasib or adagrasib in KRAS G12C–mutated NSCLC. N Engl J Med 2026; DOI: 10.1056/NEJMoa2605703
[3] Nassar AH, et al. Distribution of KRAS (G12C) Somatic Mutations across Race, Sex, and Cancer Type. N Engl J Med. 2021; 384 (2): 185-187.
[4] Lee JK, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;9;6(1):91.
[5] Wankhede D, et al. Prognostic role of KRAS G12C mutation in non-small cell lung cancer: a systematic review and meta-analysis. Diagnostics. 2023: 25;13(19): 3043.
[6] Isaksson J, et al. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry. Clin Lung Cancer. 2023: 24(6):507-518.
[7] Endres NF, et al. Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C. J Med Chem. 2026; 69 (5): 5147-5165.
[8] Friedlaender A, et al. KRAS as a druggable target in NSCLC: rising like a phoenix after decades of development failures. Cancer Treat Rev. 2020;85:101978.
[9] Pakkala S, et al. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018; 3 (15).
[10] World Health Organization. Global cancer burden growing, amidst mounting need for services [Internet; cited 2026 September]. Available from: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing–amidst-mounting-need-for-services.
[11] American Lung Association. Lung Cancer Statistics [Internet; cited 2026 September]. Available from: https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet.
[12] World Health Organization. Lung cancer [Internet; cited 2026 September]. Available from: https://www.who.int/news-room/fact-sheets/detail/lung-cancer.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz Phone: +41 79 529 70 35	Nathalie Altermatt Phone: +41 79 771 05 25
Lorena Corfas Phone: +41 79 568 24 95	Simon Goldsborough Phone: +44 797 32 72 915
Karsten Kleine Phone: +41 79 461 86 83	Kirti Pandey Phone: +41 79 398 38 53
Yvette Petillon Phone: +41 79 961 92 50	Irène Stephan Phone:  +41 79 377 83 75
Albert Thottiyil Phone: +41 79 775 66 12

Roche Investor Relations

Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

Attachment

• Media&Investor Release divarasib in KRAS G12C lung cancer English

Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline

NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs”, Stock Code: 9887.HK) today announced updated first‑in‑human clinical data for LBL‑034, its GPRC5D/CD3 bispecific T‑cell engager (TCE). The updated results were delivered in an oral presentation at the 2026 Annual Meeting of the European Society for Medical Oncology (ESMO), showcasing compelling efficacy and safety outcomes in patients with relapsed/refractory multiple myeloma (RRMM). In the effective dose range of 400–1,200 μg/kg, median progression-free survival (mPFS) reached 21.8 months, approximately twice the level reported in the pivotal studies of approved therapies against the same target.

LBL-034 demonstrated deep and durable antitumor activity across multiple difficult-to-treat patient subgroups, including those with extramedullary disease (EMD), prior exposure to BCMA-directed therapies, and extensive prior treatment. Its safety profile was characterized by predominantly low-grade cytokine release syndrome (CRS) and manageable treatment-related adverse events. These findings provide important clinical validation of the conditional T-cell redirection and activation mechanism underpinning Leads Biolabs’ proprietary LeadsBody TCE platform, supporting its continued development and potential application beyond hematologic malignancies, including autoimmune diseases and solid tumors.

Key Clinical Findings

Patient Baseline Characteristics

As of the data cutoff date of July 16, 2026, 56 patients with RRMM had been enrolled. Patients were heavily pretreated, with a median of 4.5 prior lines of therapy (range: 3–12).

• Extensive prior treatment: 73.2% of patients were triple-class exposed, 57.1% were penta-drug exposed, and 60.7% were triple-class refractory.
• Prior advanced therapies: 28.6% had received autologous stem-cell transplantation (ASCT), and 16.1% had received BCMA-directed CAR-T therapy.
• High-risk disease features: 23.2% had EMD, and 64.3% had high-risk cytogenetic abnormalities.

Overall Efficacy

Among the 41 patients treated within the effective dose range of 400–1,200 μg/kg, with a median follow-up of 17.8 months, LBL-034 demonstrated encouraging long-term disease control.

• Durable disease control: The mPFS was 21.8 months, although the PFS data remained immature at the cutoff. Median duration of response (mDoR) had not been reached.
• Sustained PFS: The 15-month and 18-month PFS rates were 62.0% and 54.8%, respectively.
• Durable responses: The 12-month and 18-month duration-of-response (DoR) rates were 77.0% and 68.4%, respectively.
• Dose-dependent depth of response: Median time to achieving complete response (CR) or better decreased with increasing dose, from 5.60 months at 400 μg/kg to 3.45 months at 800 μg/kg and 3.06 months at 1,200 μg/kg. This trend provides pharmacodynamic support for the selection of the recommended Phase 2 dose (RP2D).

Encouraging Efficacy in High‑Risk, Hard‑to‑Treat Subgroups

LBL-034 demonstrated promising antitumor activity in several patient populations with substantial unmet medical needs.

• Patients with EMD: The overall response rate (ORR) was 75.0%, with two patients achieving stringent complete response (sCR). In the 1,200 μg/kg cohort, all patients with EMD responded (ORR: 100%), accompanied by rapid and substantial reductions in extramedullary lesions.
• Patients with prior BCMA-targeted therapy failure: ORR was 85.7%, with an sCR rate of 57.1%.
• Penta-drug-exposed patients: ORR was 73.9%, with an sCR rate of 34.8%.

These results highlight the potential of LBL-034 to deliver deep clinical responses in heavily pretreated patients, including those whose disease has become resistant to established treatment approaches.

Favorable and Manageable Safety Profile

LBL-034 continued to demonstrate a favorable safety profile across the evaluated dose range.

• No dose-limiting toxicities: No dose-limiting toxicities (DLTs) were observed during dose escalation up to 1,200 μg/kg, and the maximum tolerated dose (MTD) was not reached.
• Predominantly low-grade CRS: Nearly all CRS events were low-grade, with only one Grade 3 or higher event reported.
• Manageable neurotoxicity: Two cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported; both patients recovered fully. No movement disorders or ataxia-related neurotoxic events were observed.
• Manageable treatment-emergent adverse events: Adverse events affecting quality of life were predominantly Grade 1–2. Most treatment-emergent adverse events occurred during step-up dosing and the first treatment cycle, with event rates declining substantially in subsequent cycles.
• Sustained treatment exposure: Median treatment exposure was 11.3 months, supporting the feasibility of prolonged treatment with LBL-034.

Executive Commentary

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: “The updated results presented at ESMO 2026 are highly encouraging. LBL-034 has demonstrated deep and durable clinical responses in heavily pretreated patients with RRMM, including those with high-risk features such as extramedullary disease, prior failure of BCMA-targeted therapies, and penta-drug exposure. These findings underscore the potential of LBL-034 to become a differentiated treatment option for patients with substantial unmet medical needs and support its best-in-class potential.

“We are also encouraged by the dose-dependent trend toward a shorter time to complete response or better, which provides important pharmacodynamic support for RP2D selection. The safety findings are equally meaningful: adverse events were predominantly low-grade and concentrated in the early treatment period, while treatment exposure extended to a median of 11.3 months. Together, these results support the potential for sustained treatment with LBL-034.

“Importantly, LBL-034 represents the first clinical validation of our TCE platform. The findings demonstrate the potential of our proprietary LeadsBody platform to generate TCE molecules that combine deep anti-improve responses with a manageable safety profile. Building on this milestone, we aim to advance our TCE pipeline and explore its potential across broader therapeutic areas, including autoimmune diseases and solid tumors.”

About LBL‑034

LBL‑034 is a humanized GPRC5D × CD3 bispecific T‑cell engager (TCE) generated from Leads Biolabs’ proprietary LeadsBody™ platform. It adopts a 2:1 molecular architecture: two high‑affinity GPRC5D‑targeting Fab domains paired with one CD3‑binding single‑chain variable fragment (scFv).

The molecule is engineered to selectively engage GPRC5D‑positive tumor cells and conditionally activate T‑cells. This design aims to lower risks of cytokine release, systemic toxicity and T‑cell exhaustion while delivering potent, sustained anti‑myeloma activity.

Preclinical and clinical programs have yielded promising efficacy signals for LBL‑034. Preliminary monotherapy data for RRMM were featured as an opening oral presentation at ASH 2025, and this updated dataset was selected for a proffered paper oral session at ESMO 2026. LBL‑034 secured FDA Orphan Drug Designation (ODD) in October 2024 and FDA Fast Track Designation in January 2026. Preparation work for its Phase III clinical trial is now underway.

About Leads Biolabs

Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology, autoimmune, and other severe diseases both in China and globally.

Leads Biolabs is a front-runner in next-generation immuno-oncology treatments with a differentiated pipeline of 15 innovative drug candidates, including five clinical-stage drug candidates and one registration-stage asset.

The Company adopts a science-driven R&D approach and has successfully established comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo and in vitro efficacy evaluation, as well as druggability assessment. It has also developed multiple proprietary technology platforms, including LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued innovation and have been validated by the clinical outcomes of its bispecific antibody portfolios.

Leads Biolabs has established integrated capabilities across early discovery, translational medicine, clinical development, CMC and business development. The innovative nature and competitive strengths of its drug candidates, coupled with its global perspectives, proactive strategy, and efficient clinical validation, have made it an attractive partner for leading industry players and investment institutions. For more information, please visit https://en.leadsbiolabs.com/

CONTACT: Contact:

yizi@leadsbiolabs.com

• 44.8% ORR at 6mg/kg dose in late-line CRC patients  
• ARR-217 was generally well-tolerated
• ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program

NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.

“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy,” said Bing Yao, Ph.D., Chief Executive Officer of ArriVent. “We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study. As the first ADC from our pipeline to enter clinical development, ARR-217 represents an important milestone for our ADC pipeline, and we look forward to dose optimization data expected in 2027.”

The ongoing multicenter, open-label Phase 1 study (NCT07066657) conducted in the US and China is evaluating the safety, tolerability, efficacy, and pharmacokinetics of ARR-217 in patients with unresectable, locally advanced, or metastatic solid tumors, with an initial clinical development focus in colorectal, pancreatic, and other gastrointestinal (GI) cancers. As of the August 5, 2026 data cutoff, 123 patients with heavily pretreated GI malignancies were treated across 6 dose levels ranging from 2 mg/kg to 8 mg/kg, including 113 patients with Colorectal Cancer (CRC).

Key Highlights for ARR-217 Phase 1 Study Include:

• Strong Anti-tumor Activity with ARR-217 at Multiple Dose Levels
  • At 6 mg/kg Q3W dose, 44.8% (13/29) objective response rate (ORR) observed in pre-treated CRC patients, including 7 confirmed partial responses, 4 partial responses pending confirmation, and 2 unconfirmed partial responses
  • At 6 mg/kg Q3W dose, 93.1% (27/29) disease control rate (DCR) observed
  • At doses 4 mg/kg Q3W and higher, 34.2% (25/73) ORR observed in CRC patients, including 15 confirmed partial responses, 5 partial responses pending confirmation and 5 unconfirmed partial responses
  • At doses 4 mg/kg Q3W and higher, 91.8% DCR observed
  • Majority of the responding patients remained on study treatment as of the August 5, 2026 data cutoff

• Generally, Well Tolerated Safety Profile
  • The most common treatment-related adverse events were Grade 1/2
  • Across all doses, 30.1% (37/123) patients experienced Grade 3 or higher treatment-related adverse events, including neutropenia (12.2%) and diarrhea (8.9%)
  • At 6.0 mg/kg Q3W dose, Grade 3 or higher TRAE was 20.4% (10/49) including 2.0% diarrhea (1/49)
  • No grade 5 TRAE or ILD observed

Dose Optimization and Next Steps
ARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg Q3W with further dose optimization data expected in 2027.

About ARR-217
ARR-217 (also known as MRG007) is a potentially best-in-class cadherin-17 (CDH17)-targeted antibody-drug conjugate (ADC), utilizing a glycan-linked, exatecan-based payload. CDH17 is a membranous cell adhesion molecule frequently overexpressed in colorectal cancer and several other gastrointestinal cancers, with limited expression in normal intestinal tissue and pancreatic duct, making it an attractive target for ADC therapy. ArriVent obtained exclusive rights to develop and commercialize ARR-217 worldwide outside of Greater China under a collaboration agreement with Lepu Biopharma Co., Ltd. ARR-217 is the lead clinical candidate from ArriVent’s growing ADC portfolio.

About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding, business strategy and plans; the activity safety and tolerability of ARR-217; the expected timing and future results of the ongoing clinical study of ARR-217, and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Forward-looking statements are based on ArriVent’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties that are described more fully in the section titled “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 5, 2026 and our other filings with the Securities and Exchange Commission. Forward-looking statements contained in this press release are made as of this date, and ArriVent undertakes no duty to update such information except as required under applicable law.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com